logo
Plus   Neg
Share
Email

Apricus Biosciences Gets CRL From FDA For Vitaros

Apricus Biosciences Inc. (APRI) said that the U.S. Food and Drug Administration has issued a complete response letter or "CRL" for the New Drug Application ("NDA") of Vitaros or alprostadil, DDAIP.HCl, a topical cream for the treatment of erectile dysfunction.

The CRL indicated that the FDA cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control ("CMC") and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
SCARPA North America has recalled about 4,200 ski boots due to risk of fall. The company has recalled Maestrale RS and Maestrale Men's ski boots as its shell can crack, posing a fall hazard and risk of injury to the consumer. The recall involves the Fall 2017 Maestrale RS and Maestrale Men's Ski... Walt Disney's (DIS) Frozen 2, the sequel to its 2013 blockbuster, is expected to record a strong domestic opening of over $100 million this weekend. Frozen 2 will become the 10th animated film to debut with over $100 million and the first animated film outside the summer window to hit the mark. Frozen... Indonesia is exploring a total ban on the use of electronic cigarettes and vape products in the country due to healthcare concerns following the lung illness outbreak related to vaping in the U.S., according to reports. However, the South-East Asian country has not reported any cases of vaping-related illness. Chain-smoking Indonesia is the world's second largest tobacco market.
RELATED NEWS
Follow RTT
>